Arnold G. Wong (Cofounder and Chief Executive Officer) has hands-on experience in pre-clinical research and extensive experience in clinical research. Before becoming CEO of InClin in 2014, Mr. Wong was the CFO of InClin since its’ inception in 1998. He began his career as a research scientist at Cardima, Inc., COR Therapeutics, and Syntex Research. Mr. Wong has a BS in physiology from the University of California at Davis.
Taylor T. Kilfoil (Cofounder and Chief International Officer) is the managing director of InClin PTY LTD located in Sydney Australia. Mr. Kilfoil has 25+ years of pharmaceutical and biotech industry experience. Since co-founding InClin in 1998, Mr. Kilfoil has held a wide spectrum of senior level consultant positions at multiple pharmaceutical and biotechnology companies where he provided both clinical operations and project management support for their domestic and international clinical development programs. He started his career at Syntex Research conducting pre-clinical pharmacology drug development research where he moved into the clinical research arena at CardioGenesis, Serono Australia and Syntex Australia. Mr. Kilfoil has extensive experience in Phase 1 to 3 drug development. Mr. Kilfoil has a BS in psychobiology from Saint John’s University.
Brian Horger, PhD
Brian A. Horger, PhD (Chief Operating Officer and Senior Vice President, Business Development) has broad and extensive experience in the pharmaceutical and drug development industry. Dr. Horger began his career as a Research Scientist at Yale University School of Medicine. Subsequently he held industry positions and led drug discovery efforts in Parkinson’s Disease at Genentech and smooth muscle disorders at Theravance. Over the last 10 years Dr. Horger has served as a Director of Business Development at MDS Pharma Services and Covance Early Clinical Services. Dr. Horger has a PhD in Neuroscience from Texas A&M University.
George F. Faurot (Senior Vice President, Clinical Operations) is responsible for the planning, implementation, and execution of Phase 1 to 3 clinical development programs for multiple pharmaceutical sponsors, 3 of which resulted in successful NDA approvals. He started his career at Syntex Research conducting pre-clinical toxicology drug development research where he moved into the clinical research arena at Syntex, Matrix Pharmaceutical and Oculex Pharmaceuticals. Mr. Faurot has a BS in environmental toxicology from the University of California at Davis.
Mojtaba Noursalehi, PhD
Mojtaba “Mo” Noursalehi, PhD (Senior Vice President, Biometrics) has served as Executive Director of Biometrics for Cytochroma, Astex, Exelixis, and Synteract and been responsible for managing the statistical analysis, programming, and data management activities of all phases of drug development in Oncology, Endocrinology, Transplant, and CNS. Dr. Noursalehi previously held the positions of Senior Director of Biometrics at GPC Biotech, Scirex, Clinsys, Abbott, Tercica, Target Research Associates, and Novartis. Dr. Noursalehi has also held positions of Senior Researcher at the US National Cancer Institute as well as Assistant Professor at Baker University. Dr. Noursalehi received his MSc at the University of California at Los Angeles, his PhD at the University of Kansas, and post doctorate PK/PD training from Stanford University and the University of Maryland. In his 20+ years of clinical research and pharmaceutical industry experience, he has assisted with submitting more than 20 NDAs and BLAs in various therapeutic areas.
Debora “Deb” Manuel (Vice President, Clinical Data Management) has extensive experience in the design, conduct, and analysis of clinical research studies. Ms. Manuel has over 20 years of data management experience in all phases of clinical trials in both the CRO and Sponsor environments. She has experience with numerous complicated clinical studies, and has a thorough understanding of details necessary to ensure quality data and adherence to good practices in data management. Ms. Manuel has a BS in Information Systems from the University of San Francisco.
Kim Frieze, PharmD
Kimberly A. Frieze, PharmD (Senior Vice President, Medical communications) has over 24 years’ experience in the biopharmaceutical industry, focusing in the areas of clinical research, regulatory affairs, and medical writing for drug and biologic products. Prior to joining InClin, Dr. Frieze spent 12 years at Cardinal Health Regulatory Sciences (formerly Beckloff Associates) where she was a Director of Medical Writing, managing a large team of medical writers and contributing to multiple IND, NDA, BLA, and ANDA applications. Prior to Cardinal Health, Dr. Frieze was a Principle Medical Writing Scientist at Quintiles for 5 years and a Senior Medical Writer/Senior Clinical Research Associate at Hoechst Marion Roussel (formerly Marion Merrell Dow and Marion Laboratories) for 7 years. Prior to entering the pharmaceutical industry, Dr. Frieze worked for 5 years as a clinical pharmacist, focusing in clinical oncology. Dr. Frieze is a registered pharmacist in Kansas and a member of the American Medical Writer’s Association (AMWA) and Drug Information Association (DIA). She received a doctorate in pharmacy (PharmD) and a bachelor’s degree in pharmacy from the University of Kansas School of Pharmacy in Lawrence, KS.
Tony Cruz, DVM
Tony Cruz (Vice President, Quality Assurance) has over 20 years of industry experience in quality and regulatory compliance. Tony previously held the positions of Senior Director, Development Sciences Quality and Director, Global Development Sciences Quality and Regulatory Compliance at BioMarin Pharmaceuticals, Director, Clinical Quality Management at Medivation Inc., Head, Quality Assurance and Regulatory Compliance at Naryx Pharma, and Associate Director Clinical Compliance & Training, Clinical Research & Development at Baxter BioScience. Tony received his Doctor of Veterinary Medicine (DVM) from Balagtas College of Veterinary Medicine.